Invest in the Future of Neurorehabilitation
PREMS AI Biomedical is developing the world's first closed-loop, AI-adaptive electrical muscle stimulation platform — provisionally patented, FDA-predicate cleared, and targeting a $15B+ global neurorehabilitation market.
Provisionally Patented Device
Why Invest
Key Investment Highlights
A convergence of unmet clinical need, defensible IP, and a clear regulatory pathway creates a compelling investment opportunity.
Massive Addressable Market
Over 25 million Americans live with upper or lower limb motor impairment from stroke, TBI, or spinal cord injury. The global neurorehabilitation device market is projected to exceed $15B by 2030.
Regulatory Advantage
PREMS AI is built on a 1988 FDA 510(k) predicate for proportional neuromuscular stimulation — a modernization pathway that avoids the lengthy de novo clearance process required for novel Class III devices.
Proprietary AI Platform
Our closed-loop sEMG + AI adaptive control system is provisionally patented. A single platform drives three sleeve variants — arm, hand, and lower leg — reducing development cost and accelerating time to market.
Scalable Revenue Model
Hardware sales paired with a recurring SaaS cloud telemetry subscription per device. Remote clinician oversight unlocks reimbursement pathways and drives long-term patient engagement.
Competitive Moat
Why PREMS AI Wins
Structural advantages that competitors cannot easily replicate.
Only closed-loop, AI-adaptive EMS sleeve on the market — competitors use static pre-programmed patterns
Intent-driven stimulation reinforces neuroplasticity rather than bypassing voluntary effort
Home-ready design with remote clinician oversight extends therapy beyond clinic hours
Multi-limb platform (arm, hand, lower leg) from a single AI engine — lower R&D cost per SKU
Cloud telemetry enables real-world evidence collection for payer reimbursement submissions
Provisionally patented device with defensible IP across sensing, AI control, and stimulation layers
Progress & Roadmap
Development Milestones
Provisional Patent Filed
Core closed-loop sEMG + AI adaptive control system provisionally patented.
FDA 510(k) Predicate Identified
1988 cleared predicate establishes the regulatory modernization pathway.
Three Sleeve Variants Designed
Arm, hand, and lower leg sleeves engineered on a single AI platform.
Clinical Application Mapping Complete
Target indications defined: stroke, TBI, SCI, MS, and cerebral palsy.
Pilot Clinical Study — In Planning
IRB protocol development underway for initial efficacy and safety data.
Seed Funding Round — Open
Seeking strategic investors to fund clinical validation and regulatory submission.
Investor Documents
Access Our Materials
The Pitch Deck is available for immediate download. The Business Plan and Investor Summary are available under NDA — request access below.
Business Plan
Full financial projections, go-to-market strategy, and operational roadmap. NDA required.
Request DocumentsEmail request to: wwmee52@premsai.net
Investor Summary
Executive summary of the investment thesis, valuation framework, and use of funds. NDA required.
Request DocumentsEmail request to: wwmee52@premsai.net
Ready to Learn More?
Reach out directly to discuss the investment opportunity, request NDA-gated documents, or schedule a call with the PREMS AI Biomedical team.
wwmee52@premsai.net